Verona Pharma Statistics
Total Valuation
Verona Pharma has a market cap or net worth of $1.17 billion. The enterprise value is $965.05 million.
| Market Cap | 1.17B |
| Enterprise Value | 965.05M |
Important Dates
The next estimated earnings date is Thursday, August 1, 2024, before market open.
| Earnings Date | Aug 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Verona Pharma has 75.59 million shares outstanding.
| Shares Outstanding | 75.59M |
| Owned by Insiders (%) | 3.91% |
| Owned by Institutions (%) | 88.43% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.19 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.40, with a Debt / Equity ratio of 0.23.
| Current Ratio | 18.40 |
| Quick Ratio | n/a |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.62 |
Financial Efficiency
Return on equity (ROE) is -25.10% and return on invested capital (ROIC) is -26.27%.
| Return on Equity (ROE) | -25.10% |
| Return on Assets (ROA) | -21.20% |
| Return on Capital (ROIC) | -26.27% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$802,785 |
| Employee Count | 79 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Verona Pharma has paid $1.06 million in taxes.
| Income Tax | 1.06M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.20% in the last 52 weeks. The beta is 0.34, so Verona Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | -23.20% |
| 50-Day Moving Average | 14.14 |
| 200-Day Moving Average | 15.60 |
| Relative Strength Index (RSI) | 56.48 |
| Average Volume (20 Days) | 1,917,046 |
Short Selling Information
| Short Interest | 7.72M |
| Short Previous Month | 6.00M |
| Short % of Shares Out | 9.94% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.78 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -72.57M |
| Pretax Income | -62.37M |
| Net Income | -63.42M |
| EBITDA | -58.23M |
| EBIT | -59.02M |
| Earnings Per Share (EPS) | -$0.80 |
Balance Sheet
The company has $254.88 million in cash and $51.27 million in debt, giving a net cash position of $203.61 million or $2.69 per share.
| Cash & Cash Equivalents | 254.88M |
| Total Debt | 51.27M |
| Net Cash | 203.61M |
| Net Cash Per Share | $2.69 |
| Equity (Book Value) | 224.99M |
| Book Value Per Share | 2.98 |
| Working Capital | 257.07M |
Cash Flow
In the last 12 months, operating cash flow was -$58.05 million and capital expenditures -$16,000, giving a free cash flow of -$58.07 million.
| Operating Cash Flow | -58.05M |
| Capital Expenditures | -16,000 |
| Free Cash Flow | -58.07M |
| FCF Per Share | -$0.72 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Verona Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.90% |
| Shareholder Yield | -3.90% |
| Earnings Yield | -5.43% |
| FCF Yield | -4.97% |
Analyst Forecast
The average price target for Verona Pharma is $35.00, which is 126.39% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.00 |
| Price Target Difference | 126.39% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |